

AMENDMENTS TO THE CLAIMS

1-15. (Cancelled)

16. (Currently Amended) A method for screening a compound which is able to mitigate or treat renal glomerular lesions, lesions of pancreatic islets of Langerhans or epidermal lesions, which comprises measuring a promoting action of a test compound ~~to be tested~~ on the induction of regeneration-promoting CD11b⁺CD2⁺ macrophages and regulatory CD2⁻CD4⁺ T lymphocytes, in the presence of ~~caused by contact of~~ human peripheral blood mononuclear cells ~~with and~~ a lipopolysaccharide.

17. (Withdrawn) A method for screening a compound which is able to prevent, mitigate or treat renal tubulointerstitial lesions, lesions of pancreatic exocrine or interstitial tissues, or dermal lesions, which comprises measuring a promoting action of a compound to be tested on the induction of regeneration-promoting CD11b⁻CD2⁺ macrophages and/or regulatory CD2⁻CD4⁺ T lymphocytes caused by contact of human peripheral blood mononuclear cells with mitomycin-treated human peripheral blood mononuclear cells.

18-20. (Cancelled)

21. (Withdrawn) A method for suppression and/or regeneration of sclerotic lesions causing apoptosis, degeneration, fibrosis and atrophy, which comprises administering a compound which preferentially increases regeneration-promoting macrophages to a patient.

22. (Withdrawn) A therapeutic method for renal glomerular lesions, lesions of pancreatic islets of Langerhans or epidermal lesions, which comprises administering a

pharmaceutical comprising a compound which promotes induction of regeneration-promoting CD11b⁺CD2⁺ macrophages to a patient.

23. (Withdrawn) The therapeutic method as claimed in claim 22, wherein the compound which preferentially increases regeneration-promoting CD11b⁺CD2⁺ macrophages is one or more compound(s) selected from the group consisting of (R)-1-naphthalen-2-ylethyl (R)-2-(4-fluorophenoxy)-5-oxotetrahydrofuran-2-carboxylate, 2-fluoro-5-oxotetrahydrofuran-2-carboxylic acid benzyl ester, bacitracin A, viomycin, 6,7-dimethoxy-1-morpholinomethyl-isochromane, 1-diethylaminomethyl-5-butoxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(4-fluorophenylthio)-2-methylaminopropanone, 2-chloro-5-oxotetrahydrofuran-2-carboxylic acid benzyl ester and 1-(2-oxo-hemiglutaric acid) benzyl ester.

24. (Withdrawn) A therapeutic method for renal tubulointerstitial lesions, lesions of pancreatic exocrine or interstitial tissues, or dermal lesions, which comprises administering a pharmaceutical comprising a compound which promotes induction of regeneration-promoting CD11b⁺CD2⁺ macrophages to a patient.

25. (Withdrawn) The therapeutic method as claimed in claim 24, wherein the compound promoting induction of regeneration-promoting CD11b⁺CD2⁺ macrophages is one or more compound(s) selected from the group consisting of (R)-1-naphthalen-2-ylethyl (S)-2-(4-fluorophenoxy)-5-oxotetrahydrofuran-2-carboxylate, 2-benzyl-5-oxo-2-tetrahydrofurancarboxylic acid benzyl ester, 1-chloro-3-oxo-1,3-dihydroisobenzofuran-1-carboxylic acid benzyl ester and 1-(2-oxo-hemiglutaric acid) ethyl ester.

26. (Withdrawn) A therapeutic method for kidney diseases, pancreatic diseases or skin diseases, which comprises concurrently administering a compound which promotes induction of regeneration-promoting CD11b⁺CD2⁺ macrophages and a compound which

promotes induction of regeneration-promoting CD11b⁻CD2⁺ macrophages to a patient.

27. (Withdrawn) A therapeutic method for kidney diseases, pancreatic diseases or skin diseases, which comprises administering a compound which promotes induction of regeneration-promoting CD11b⁺CD2⁺ macrophages and regeneration-promoting CD11b⁻CD2⁺ macrophages to a patient.

28. (Withdrawn) The therapeutic method as claimed in claim 27, which comprises concurrently administering a compound promoting induction of regeneration-promoting CD11b⁺CD2⁺ macrophages and a compound promoting induction of regeneration-promoting CD11b⁻CD2⁺ macrophages, each of which being one or more compound(s) selected from the group consisting of

2-(4-chlorophenyl)thio-5-oxo-2-tetrahydrofuran carboxylic acid benzyl ester,
2-(4-fluorophenyl)oxy-5-oxo-2-tetrahydrofurancarboxylic acid ethyl ester,
2-(2,4-difluorophenyl)sulfonyl-5-oxo-2-tetrahydrofurancarboxylic acid benzyl ester,
2-phenoxy-5-oxo-2-tetrahydrofurancarboxylic acid benzhydryl ester,
2-(4-fluorophenyl)thio-5-oxo-2-tetrahydrofurancarboxylic acid,
2-(4-methoxyphenyl)thio-5-oxo-2-tetrahydrofurancarboxylic acid,
2-(2,4-difluorophenyl)thio-5-oxo-2-tetrahydrofurancarboxylic acid and 2-(4-fluorophenyl)sulfonyl-5-oxo-2-tetrahydrofurancarboxylic acid benzyl ester, to a patient.

29-38. (Cancelled)

39. (Previously presented) The method according to claim 16, wherein to mitigate or treat is to treat.

40. (Previously presented) The method according to claim 16, wherein the lesions of pancreatic islets of Langerhans or epidermal lesions are epidermal lesions.

41. (Currently amended) The method according to claim 40, wherein the epidermal lesions are cuts, traumas, ulcers or wounds of epidermides.

42. (Previously presented) The method according to claim 16, which comprises inducing regeneration-promoting $CD11b^{+}CD2^{+}$ macrophages and regulatory $CD2^{-}CD4^{+}$ T lymphocytes by cultivating human peripheral blood mononuclear leukocytes in a medium in the presence of the test compound, lipopolysaccharide and human AB type serum, measuring numbers of $CD11b^{+}CD2^{+}$ macrophages and regulatory $CD2^{-}CD4^{+}$ T lymphocytes, comparing the numbers with numbers measured in the absence of the test compound, and selecting a test compound which increases the numbers of $CD11b^{+}CD2^{+}$ macrophages and regulatory $CD2^{-}CD4^{+}$ T lymphocytes.

43. (Previously presented) The method according to claim 42, which comprises selecting a test compound which increases the numbers of $CD11b^{+}CD2^{+}$ macrophages and regulatory $CD2^{-}CD4^{+}$ T lymphocytes at a ratio not less than 20% compared with the numbers of $CD11b^{+}CD2^{+}$ macrophages and regulatory $CD2^{-}CD4^{+}$ T lymphocytes measured in the absence of the test compound.

44. (New) The method according to claim 16, wherein the lesions of renal glomerular lesions, pancreatic islets of Langerhans or epidermal lesions are pancreatic islets of Langerhans or epidermal lesions.